Literature DB >> 18342402

Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.

Silvia Schenone1, Chiara Brullo, Olga Bruno, Francesco Bondavalli, Luisa Mosti, Giovanni Maga, Emmanuele Crespan, Fabio Carraro, Fabrizio Manetti, Cristina Tintori, Maurizio Botta.   

Abstract

The synthesis of new 4-amino substituted pyrazolo[3,4-d]pyrimidines along with their activity in cell-free enzymatic assays on Src and Abl tyrosine kinases is reported. Some compounds emerged as good dual inhibitors of the two enzymes, showed antiproliferative effects on two Bcr-Abl positive leukemia cell lines K-562 and KU-812, and induced apoptosis, as demonstrated by the PARP assay. Docking studies have been also performed to analyze the binding mode of compounds under study and to identify the structural determinants of their interaction with both Src and Abl.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342402     DOI: 10.1016/j.ejmech.2008.01.034

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.

Authors:  Alessandra Rossi; Silvia Schenone; Adriano Angelucci; Martina Cozzi; Valentina Caracciolo; Francesca Pentimalli; Andrew Puca; Biagio Pucci; Raffaele La Montagna; Mauro Bologna; Maurizio Botta; Antonio Giordano
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

2.  Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.

Authors:  Giulia Vignaroli; Claudio Zamperini; Elena Dreassi; Marco Radi; Adriano Angelucci; Patrizia Sanità; Emmanuele Crespan; Miroslava Kissova; Giovanni Maga; Silvia Schenone; Francesca Musumeci; Maurizio Botta
Journal:  ACS Med Chem Lett       Date:  2013-05-20       Impact factor: 4.345

3.  Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.

Authors:  Rohan Patil; Suranjana Das; Ashley Stanley; Lumbani Yadav; Akulapalli Sudhakar; Ashok K Varma
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

4.  Design, Synthesis, and Antitumor Evaluation of Novel Pyrazolo[3,4-d]pyrimidine Derivatives.

Authors:  Manal M Kandeel; Lamia W Mohamed; Mohammed K Abd El Hamid; Ahmed T Negmeldin
Journal:  Sci Pharm       Date:  2012-06-25

5.  Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.

Authors:  Thomas Kruewel; Silvia Schenone; Marco Radi; Giovanni Maga; Astrid Rohrbeck; Maurizio Botta; Juergen Borlak
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

6.  Synthesis and anticancer evaluation of some novel pyrimido[5,4-e][1,2,4]triazines and pyrazolo[3,4-d]pyrimidine using DMF-DMA as methylating and cyclizing agent.

Authors:  Samar A El-Kalyoubi
Journal:  Chem Cent J       Date:  2018-05-23       Impact factor: 4.215

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.